Literature DB >> 17505130

Pulmonary hypertension in sickle-cell disease: comorbidities and echocardiographic findings.

Ferit Akgül1, Fatih Yalçin, Ergün Seyfeli, Edip Uçar, Sinem Karazincir, Ali Balci, Edip Gali.   

Abstract

BACKGROUND: Our aim is to determine comorbidities associated with pulmonary hypertension (PHT) in clinically stable sickle-cell disease (SCD) patients and to evaluate left ventricular (LV) and right ventricular (RV) function in those patients.
METHODS: Echocardiography was performed in 87 SCD patients that were divided into group I (without PHT) and group II (with PHT). Both groups were compared with healthy controls.
RESULTS: A history of retinopathy and leg ulcer was more frequent in group II than group I (p < 0.01). Haemoglobin levels were lower (p < 0.05), whereas blood urea nitrogen, lactate dehydrogenase and total bilirubin levels were higher in group II (p < 0.01). Although group II patients had larger LV end-diastolic, LV end-systolic and RV diastolic diameters compared with group I patients and controls (p < 0.05), LV ejection fraction was similar in the three groups. The mitral peak early diastolic inflow velocity to peak late diastolic inflow velocity (E/A) ratio was similar in group I, group II and the control group. The tricuspid E/A ratio was lower in group II than group I and controls (p < 0.05).
CONCLUSION: End organ damage occurs more often and haemolysis is severer in SCD patients with PHT than SCD patients without PHT. Although LV systolic and diastolic function is well preserved, RV diastolic function is disturbed in those patients with PHT. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17505130     DOI: 10.1159/000102588

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  8 in total

1.  Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension.

Authors:  Yinzhong Zhang; Arunabh Talwar; Donna Tsang; Annette Bruchfeld; Ali Sadoughi; Maowen Hu; Kennedy Omonuwa; Kai Fan Cheng; Yousef Al-Abed; Edmund J Miller
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

2.  TRV: a physiological biomarker in sickle cell disease.

Authors:  Gregory J Kato
Journal:  Pediatr Blood Cancer       Date:  2011-12-16       Impact factor: 3.167

3.  Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition.

Authors:  Jane S Hankins; Mary Beth McCarville; Claudia M Hillenbrand; Ralf B Loeffler; Russell E Ware; Ruitian Song; Matthew P Smeltzer; Vijaya Joshi
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

4.  Incidence of eye complications among sickle cell disease patients in Jeddah, Saudi Arabia: A cross-sectional study.

Authors:  Eid Ayed Almasoudi; Sultan Fahad Magliah; Abubakr Salem Alzwaihri; Abdullah Omar Aljuwaybiri; Abdullah Saleh Alqahtani
Journal:  Ann Med Surg (Lond)       Date:  2022-06-21

5.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

6.  Vascular dysfunction in a murine model of severe hemolysis.

Authors:  Anne C Frei; YiHe Guo; Deron W Jones; Kirkwood A Pritchard; Karen A Fagan; Neil Hogg; Nancy J Wandersee
Journal:  Blood       Date:  2008-05-13       Impact factor: 22.113

7.  Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.

Authors:  Victor R Gordeuk; Andrew Campbell; Sohail Rana; Mehdi Nouraie; Xiaomei Niu; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; Onyinye Onyekwere; Tatiana Ammosova; Sergei Nekhai; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

Review 8.  Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure.

Authors:  Katherine C Wood; Mark T Gladwin; Adam C Straub
Journal:  Heart       Date:  2019-12-10       Impact factor: 5.994

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.